Once-weekly icodec injections showed non inferiority to once-daily injections of degludec in a Phase III clinical trial.
List view / Grid view
A new method enabling biological materials to be stored in a solid-state means medicines such as insulin could be administered orally in the future.
Insulin for at least one million diabetics in low- and middle-income countries, mainly in Africa, is the aim of Eli Lilly and EVA Pharmaceutical's new collaboration.
Sanofi Global Health — a nonprofit unit of Sanofi set up in 2021 — has launched Impact®, a new brand of standard of care medicines dedicated for nonprofit distribution in 40 of the world’s lower-income countries.
Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.
How close are we to oral biologic drug delivery? Will biomedical devices be essential in overcoming drug delivery challenges? Discover all this and more in this podcast with MIT's Assistant Professor Giovanni Traverso.
An innovative new pill can deliver large quantities of monoclonal antibodies and other drugs into the stomach lining after swallowing.
The first interchangeable biosimilar insulin product will help increase access and affordability of insulin for diabetics.
Researchers say that their novel way to produce synthetic insulin could also be used to create at least eight other drugs.
Novo Nordisk has set up a programme to allow patients in the US experiencing financial hardship because of COVID-19 to receive free insulin for 90 days.
Dr Sam Roscoe explains his recommendations for pharmaceutical companies and supermarkets in the UK to limit reliance on deliveries from overseas, to ease the impact of the COVID-19 coronavirus on drug supply chains.
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.